Cowen and Company’s ZyVersa Therapeutics ZVSA Stock Holding History

Cowen and Company’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-143	Closed	-$6.47K	–	685
2023 Q3	$6.47K	Hold	143	–	–	﹤0.01%	506
2023 Q2	$12.3K	Buy	+143	New	+$37.5K	﹤0.01%	379

Other funds holding ZVSA

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cowen and Company's ZVSA Position: Q4 2023 in Review

Cowen and Company sold out of ZyVersa Therapeutics (ZVSA) in Q4 2023, closing a stake of 143 shares — an estimated $6.47K sold.

Cowen and Company first reported a position in ZVSA in Q2 2023 and held it in 2 quarters. The position peaked at $12.3K in Q2 2023. 6 funds tracked by Wall St. Rank hold ZVSA as of Q4 2023.

Cowen and Company reported no remaining ZyVersa Therapeutics position as of Q4 2023 after selling out during the quarter.
Cowen and Company sold 143 ZyVersa Therapeutics shares in Q4 2023, an estimated $6.47K.
Cowen and Company first reported a position in ZyVersa Therapeutics in Q2 2023 and held it in 2 quarters.
Cowen and Company's ZyVersa Therapeutics position peaked at $12.3K in Q2 2023.
6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2023.

Based on Cowen and Company's 13F filing for Q4 2023, filed 8 Feb 2024.